Cargando…
A review of flash glucose monitoring in type 2 diabetes
BACKGROUND: Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy. MAIN BODY: The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, Uni...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035716/ https://www.ncbi.nlm.nih.gov/pubmed/33836819 http://dx.doi.org/10.1186/s13098-021-00654-3 |
_version_ | 1783676758098182144 |
---|---|
author | Krakauer, Marcio Botero, Jose Fernando Lavalle-González, Fernando J. Proietti, Adrian Barbieri, Douglas Eugenio |
author_facet | Krakauer, Marcio Botero, Jose Fernando Lavalle-González, Fernando J. Proietti, Adrian Barbieri, Douglas Eugenio |
author_sort | Krakauer, Marcio |
collection | PubMed |
description | BACKGROUND: Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy. MAIN BODY: The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, United Kingdom) consists of a factory-calibrated sensor worn on the back of the arm which measures glucose levels in the interstitial fluid every minute and stores the reading automatically every 15 min. Swiping the reader device over the sensor retrieves stored data and displays current interstitial glucose levels, a glucose trend arrow, and a graph of glucose readings over the preceding 8 h. In patients with type 2 diabetes (T2D) receiving insulin therapy, pivotal efficacy data were provided by the 6-month REPLACE randomized controlled trial (RCT) and 6-month extension study. Compared to SMBG, the flash system significantly reduced the time spent in hypoglycemia and frequency of hypoglycemic events, although no significant change was observed in glycosylated hemoglobin (HbA1c) levels. Subsequent RCTs and real-world chart review studies have since shown that flash glucose monitoring significantly reduces HbA1c from baseline. Real-world studies in both type 1 diabetes or T2D populations also showed that flash glucose monitoring improved glycemic control. Higher (versus lower) scanning frequency was associated with significantly greater reductions in HbA1c and significant improvements in other measures such as time spent in hypoglycemia, time spent in hyperglycemia, and time in range. Additional benefits associated with flash glucose monitoring versus SMBG include reductions in acute diabetes events, all-cause hospitalizations and hospitalized ketoacidosis episodes; improved well-being and decreased disease burden; and greater treatment satisfaction. CONCLUSION: T2D patients who use flash glucose monitoring might expect to achieve significant improvement in HbA1c and glycemic parameters and several associated benefits. |
format | Online Article Text |
id | pubmed-8035716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80357162021-04-12 A review of flash glucose monitoring in type 2 diabetes Krakauer, Marcio Botero, Jose Fernando Lavalle-González, Fernando J. Proietti, Adrian Barbieri, Douglas Eugenio Diabetol Metab Syndr Review BACKGROUND: Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy. MAIN BODY: The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, United Kingdom) consists of a factory-calibrated sensor worn on the back of the arm which measures glucose levels in the interstitial fluid every minute and stores the reading automatically every 15 min. Swiping the reader device over the sensor retrieves stored data and displays current interstitial glucose levels, a glucose trend arrow, and a graph of glucose readings over the preceding 8 h. In patients with type 2 diabetes (T2D) receiving insulin therapy, pivotal efficacy data were provided by the 6-month REPLACE randomized controlled trial (RCT) and 6-month extension study. Compared to SMBG, the flash system significantly reduced the time spent in hypoglycemia and frequency of hypoglycemic events, although no significant change was observed in glycosylated hemoglobin (HbA1c) levels. Subsequent RCTs and real-world chart review studies have since shown that flash glucose monitoring significantly reduces HbA1c from baseline. Real-world studies in both type 1 diabetes or T2D populations also showed that flash glucose monitoring improved glycemic control. Higher (versus lower) scanning frequency was associated with significantly greater reductions in HbA1c and significant improvements in other measures such as time spent in hypoglycemia, time spent in hyperglycemia, and time in range. Additional benefits associated with flash glucose monitoring versus SMBG include reductions in acute diabetes events, all-cause hospitalizations and hospitalized ketoacidosis episodes; improved well-being and decreased disease burden; and greater treatment satisfaction. CONCLUSION: T2D patients who use flash glucose monitoring might expect to achieve significant improvement in HbA1c and glycemic parameters and several associated benefits. BioMed Central 2021-04-09 /pmc/articles/PMC8035716/ /pubmed/33836819 http://dx.doi.org/10.1186/s13098-021-00654-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Krakauer, Marcio Botero, Jose Fernando Lavalle-González, Fernando J. Proietti, Adrian Barbieri, Douglas Eugenio A review of flash glucose monitoring in type 2 diabetes |
title | A review of flash glucose monitoring in type 2 diabetes |
title_full | A review of flash glucose monitoring in type 2 diabetes |
title_fullStr | A review of flash glucose monitoring in type 2 diabetes |
title_full_unstemmed | A review of flash glucose monitoring in type 2 diabetes |
title_short | A review of flash glucose monitoring in type 2 diabetes |
title_sort | review of flash glucose monitoring in type 2 diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035716/ https://www.ncbi.nlm.nih.gov/pubmed/33836819 http://dx.doi.org/10.1186/s13098-021-00654-3 |
work_keys_str_mv | AT krakauermarcio areviewofflashglucosemonitoringintype2diabetes AT boterojosefernando areviewofflashglucosemonitoringintype2diabetes AT lavallegonzalezfernandoj areviewofflashglucosemonitoringintype2diabetes AT proiettiadrian areviewofflashglucosemonitoringintype2diabetes AT barbieridouglaseugenio areviewofflashglucosemonitoringintype2diabetes AT krakauermarcio reviewofflashglucosemonitoringintype2diabetes AT boterojosefernando reviewofflashglucosemonitoringintype2diabetes AT lavallegonzalezfernandoj reviewofflashglucosemonitoringintype2diabetes AT proiettiadrian reviewofflashglucosemonitoringintype2diabetes AT barbieridouglaseugenio reviewofflashglucosemonitoringintype2diabetes |